Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Effects of Very Early Use of Rosuvastatin in Preventing Recurrence of Ischemic Stroke (EUREKA)

This study has been terminated.
(Slow enrollment)
Sponsor:
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
Ji Hoe Heo, Severance Hospital
ClinicalTrials.gov Identifier:
NCT01364220
First received: May 26, 2011
Last updated: November 19, 2014
Last verified: November 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: April 2013
  Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)